CTRI/2020/06/025960.

Methods	Trial design: open‐label RCT with 2 parallel arms Type of record: trial register entry Sample size: 100 Setting: inpatient Country: India Language: English Number of centres: 1 Study purpose (treatment, prevention): treatment Trial registration number: NextCTRI/2020/06/025960 Date of registration: 18 June 2020
Participants	Inclusion criteria Symptomatic people infected with SARS‐CoV‐2 virus diagnosed on RT‐PCR test, admitted to hospital Age 18–70 years Exclusion criteria Age < 18 and > 70 years Pregnant and lactating women Unwilling to give written informed consent Seriously‐ill people requiring intensive care Known hypersensitivity to ivermectin People who have participated in another investigational drug or research study within 30 days of screening People who are using any medication or has any disease which in the judgement of the Investigator will interfere with the conduct or interpretation of the study
Interventions	Details of intervention Type and dose: ivermectin 12 mg, once daily for 3 days Route of administration: oral Treatment details of control group Standard of care, no details provided Concomitant therapy: NR
Outcomes	Primary study outcome Eradication of virus by testing for SARS‐CoV‐2 by RT‐PCR test at 7 days Relevant review outcomes planned Viral clearance at 7 days Safety of ivermectin within 15 days Additional study outcomes Duration of hospitalization Reduction in inflammatory markers at days 1, 5, and 10 Resolution of signs and symptoms of COVID‐19 at 3, 5, and 10 days
Notes	Reason for awaiting classification: unclear if standard of care administered in ivermectin group Recruitment status: not yet recruiting Prospective completion date: NR Planned completion date more than 6 months ago: unclear Date last update posted: 17 June 2020 Sponsor/funding: Symbiosis Medical College for Women, Lavale